Abcam, ab266577, Human LUC7L2 knockout HEK-293T cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
LUC7L2 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LUC7L2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LUC7L2 also known as LUC7-like 2 is an RNA-binding protein that plays a role in RNA splicing. It has a molecular mass of approximately 27 kDa. LUC7L2 is expressed in a variety of tissues with a higher expression in the brain and reproductive tissues. It has a specific domain structure that enables it to bind to RNA molecules influencing pre-mRNA processing. The protein is also known to interact with other splicing factors contributing to its function in the cellular nucleus.
Biological function summary
LUC7L2 is an important factor in the regulation of gene expression. It is part of the spliceosome complex which is responsible for the precisely regulated removal of introns from pre-mRNA. This activity impacts the generation of mature mRNA and consequently protein synthesis. LUC7L2 interacts with other components of the spliceosome like the U1 snRNP which ensures accurate and efficient splicing. Through these interactions LUC7L2 helps maintain the fidelity of the splicing process affecting cell function and health.
Pathways
LUC7L2 participates in the mRNA splicing pathway also known as the spliceosome cycle. This protein is involved in both the recognition of splice sites and the catalytic steps of splicing. LUC7L2's activity influences alternative splicing patterns which diversifies the proteome. It interacts with other proteins like the SR proteins which modulate splicing decisions. Its role in the spliceosome cycle highlights its contribution to gene expression regulation.
LUC7L2 has been implicated in neurological disorders and certain cancers. Alterations in LUC7L2 expression or function can lead to aberrant splicing events that disrupt normal cellular activity. In some cancers LUC7L2's interaction with proteins like SF3B1 another spliceosomal component becomes dysregulated contributing to tumorigenesis. Understanding LUC7L2's function and interactions may help develop therapeutic strategies for conditions linked to splicing dysregulation.